Cognitive Disorders

Explore effective strategies for dementia risk reduction and understand the importance of early cognitive assessments in aging adults.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Learn more about key findings on sex differences in cognition, exploring the possible causes and implications for clinical practice.

Disruptions to cognitive control, as well as to emotional processes, are implicated in a wide range of psychiatric disorders.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Review various aspects of cognition in our latest Special Report.

For older adults, hoarding disorder can have serious consequences. Examine this case study to learn more.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

For the past 7 decades, there has only been 1 mechanism of action for schizophrenia treatment. Christoph Correll, MD, talks new options and cognitive impairment at the 2024 APA Annual Meeting.

The current system of extrajudicial medical holds does not protect the rights of those who lack capacity to care for themselves due a medical condition.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

The screening tool includes multiple tests that assess memory, attention, executive function, reaction times, and motor function.

A new study correlates reduced serotonin transporter and increased amyloid-ß deposition with cognitive deficits in mild cognitive impairment, suggesting a role for serotonergics in early Alzheimer disease.

What is new in research on sleep?

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

A new cognitive biotype for depression may impact symptoms and treatment outcomes.

A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.

What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?

Are you ready to understand how recovery-oriented cognitive therapy (CT-R) promotes wellness and empowerment for individuals experiencing serious mental health challenges? Check out this CME article.

VR-based training may help improve social cognition and functioning in patients with schizophrenia.

What's the latest in dementia?

Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.